Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23576706 | 1.00 | PTGS2 (0.38) | PTGS2PTGS1LRRK2ACSS2TP53 | |
| SCHEMBL23600998 | 0.84 | NR3C2 (0.51) | — | |
| SCHEMBL23600982 | 0.83 | HTR6 (0.39) | PDE5ACSNK2A1CSNK2A2CSNK2BMAPT | |
| SCHEMBL23600977 | 0.83 | MAPT (0.39) | PDE5AMAPTSMN1; SMN2 | |
| SCHEMBL30961043 | 0.83 | MAPT (0.39) | PDE5AMAPTSMN1; SMN2 | |
| SCHEMBL23600979 | 0.82 | EGFR (0.44) | PDE5ACSNK2A1CSNK2A2CSNK2BMAPT | |
| SCHEMBL23577065 | 0.82 | PDE5A (0.36) | PDE5ACSNK2A1CSNK2A2CSNK2BMAPT | |
| SCHEMBL23577125 | 0.82 | PDE5A (0.42) | PDE5ACSNK2A1CSNK2A2CSNK2BPOLB | |
| SCHEMBL23577341 | 0.82 | PDE5A (0.36) | PDE5ACSNK2A1CSNK2A2CSNK2BMAPT | |
| SCHEMBL23576963 | 0.82 | ABCG2 (0.42) | PDE5ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | PTGS2 1810/4885PTGS1 1792/4885LRRK2 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.